May 17, 2020

Sun Ends Efforts To Buyout Taro Pharma

Sun Pharmaceuticals
Taro Pharmaceuticals
Acquisition
buyo
Admin
1 min
Growth At Taro Pharma Puts End To Sun Buyout Deal
Sun Pharmaceutical Industries has ended its effort to buy the remaining stock of Taro Pharmaceutical Industries for approximately $685 million after T...

 

Sun Pharmaceutical Industries has ended its effort to buy the remaining stock of Taro Pharmaceutical Industries for approximately $685 million after Taro shareholders held out for a higher price.

Sun and Taro releases a joint statement today saying that terminating the $39.50 a-share merger agreement “was in the best interest of the respective companies and shareholders.” The board of Yakum, Israel-based Taro had initially agreed to the deal in August after rejecting a $24.50 a-share proposal in July. Sun, based in Mumbai, already owns 61 percent of Taro.

Sun Pharma, India’s largest drug maker by market value, has been trying to close a deal with Taro for six years. When the pharma giant first began bidding for Taro in 2007 it was losing money; however, since the company has become profitable and even before it agreed in August for Sun to buy the remaining shares, Taro’s stock price surpassed the offer price.  

Taro shares rose 0.2 percent to close at $50.55 in New York trading yesterday.

Read Related Articles On Healthcare Global

Share article

Jun 15, 2021

 NHS trials test that predicts sepsis 3 days in advance 

sepsis
MachineLearning
clinicaltrial
blooddisorder
2 min
Queen Alexandra Hospital is trialling a new sepsis test by Presymptom Health that uses machine learning to detect the onset of the disease

A new test that can predict sepsis before the patient develops symptoms is being trialled at a National Health Service (NHS) hospital in the south of England. 

Clinicians at Portsmouth’s Queen Alexandra Hospital are leading medical trials of the blood test, which they hope will help them save thousands of lives a year. 

The test is being developed by government spin-out company Presymptom Health, but the research began over 10 years ago at the Defence Science and Technology Laboratory (Dstl). This included a study of 4,385 patients and more than 70,000 samples, the largest study of its kind at the time. 

From the samples taken, a clinical biobank and database were generated and then mined using machine learning to identify biomarker signatures that could predict the onset of sepsis. The researchers found they were able to provide an early warning of sepsis up to three days ahead of illness with an accuracy of up to 90%.

Unlike most other tests, Presymptom Health identifies the patient’s response to the disease as opposed to detecting the pathogen. This is an important differentiator, as sepsis occurs as a result of the patient's immune system’s overreaction to an infection or injury, which can then cause life-threatening organ dysfunction. 

Worldwide, an estimated 49 million people a year contract sepsis, while in the UK almost two million patients admitted to hospital each year are thought to be at risk of developing the condition. If Presymptom's test is effective, it could save billions of pounds globally and improve clinical outcomes for millions of sepsis patients.

The initial trials at Queen Alexandra Hospital will last 12 months, with two other sites planned to go live this summer. Up to 600 patients admitted to hospital with respiratory tract infections will be given the option to participate in the trial. The data collected will be independently assessed and used to refine and validate the test, which could be available for broader NHS use within two years. 

If successful, this test could also identify sepsis arising from other infections before symptoms appear, which could potentially include future waves of COVID-19 and other pandemics.

Dr Roman Lukaszewski, the lead Dstl scientist behind the innovation, said: “It is incredible to see this test, which we had originally begun to develop to help service personnel survive injury and infection on the front line, is now being used for the wider UK population, including those fighting COVID-19.”

Share article